» Articles » PMID: 33322092

Establishment and Preliminary Characterization of Three Astrocytic Cells Lines Obtained from Primary Rat Astrocytes by Sub-Cloning

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2020 Dec 16
PMID 33322092
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Gliomas are complex and heterogeneous tumors that originate from the glial cells of the brain. The malignant cells undergo deep modifications of their metabolism, and acquire the capacity to invade the brain parenchyma and to induce epigenetic modifications in the other brain cell types. In spite of the efforts made to define the pathology at the molecular level, and to set novel approaches to reach the infiltrating cells, gliomas are still fatal. In order to gain a better knowledge of the cellular events that accompany astrocyte transformation, we developed three increasingly transformed astrocyte cell lines, starting from primary rat cortical astrocytes, and analyzed them at the cytogenetic and epigenetic level. In parallel, we also studied the expression of the differentiation-related H1.0 linker histone variant to evaluate its possible modification in relation with transformation. We found that the most modified astrocytes (A-FC6) have epigenetic and chromosomal alterations typical of cancer, and that the other two clones (A-GS1 and A-VV5) have intermediate properties. Surprisingly, the differentiation-specific somatic histone H1.0 steadily increases from the normal astrocytes to the most transformed ones. As a whole, our results suggest that these three cell lines, together with the starting primary cells, constitute a potential model for studying glioma development.

Citing Articles

Enzymatic TET-1 inhibition highlights different epigenetic behaviours of IL-1β and TNFα in tumour progression of OS cell lines.

Bellavia D, Caruccio S, Caradonna F, Costa V, Urzi O, Raimondi L Clin Epigenetics. 2024; 16(1):136.

PMID: 39358792 PMC: 11448002. DOI: 10.1186/s13148-024-01745-4.


An alternative approach of TUNEL assay to specifically characterize DNA fragmentation in cell model systems.

Naselli F, Cardinale P, Volpes S, Martino C, Cruciata I, Valenti R Histochem Cell Biol. 2024; 162(5):429-442.

PMID: 38940846 PMC: 11393043. DOI: 10.1007/s00418-024-02306-9.


Effects of Cerebrospinal Fluids from Alzheimer and Non-Alzheimer Patients on Neurons-Astrocytes-Microglia Co-Culture.

Iemmolo M, Bivona G, Piccoli T, Nicosia A, Schiera G, Di Liegro C Int J Mol Sci. 2024; 25(5).

PMID: 38473758 PMC: 10931816. DOI: 10.3390/ijms25052510.


Contribution of histone variants to aneuploidy: a cancer perspective.

Ragusa D, Vagnarelli P Front Genet. 2023; 14:1290903.

PMID: 38075697 PMC: 10702394. DOI: 10.3389/fgene.2023.1290903.


An In Vitro Model of Glioma Development.

Schiera G, Cancemi P, Di Liegro C, Naselli F, Volpes S, Cruciata I Genes (Basel). 2023; 14(5).

PMID: 37239349 PMC: 10217752. DOI: 10.3390/genes14050990.


References
1.
Nastasi T, Scaturro M, Bellafiore M, Raimondi L, Beccari S, Cestelli A . PIPPin is a brain-specific protein that contains a cold-shock domain and binds specifically to H1 degrees and H3.3 mRNAs. J Biol Chem. 1999; 274(34):24087-93. DOI: 10.1074/jbc.274.34.24087. View

2.
Chamorro J, Castagnino J, Aidar O, Musella R, Frias A, Visca M . Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics. 2017; 27(10):363-371. DOI: 10.1097/FPC.0000000000000300. View

3.
Librizzi M, Chiarelli R, Bosco L, Sansook S, Gascon J, Spencer J . The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells. Materials (Basel). 2017; 8(10):7041-7047. PMC: 5455366. DOI: 10.3390/ma8105358. View

4.
Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini P . 2011: the immune hallmarks of cancer. Cancer Immunol Immunother. 2011; 60(3):319-26. PMC: 3042096. DOI: 10.1007/s00262-010-0968-0. View

5.
Eckel-Passow J, Lachance D, Molinaro A, Walsh K, Decker P, Sicotte H . Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015; 372(26):2499-508. PMC: 4489704. DOI: 10.1056/NEJMoa1407279. View